# Molecular Modeling as a Tool for Understanding Human Health Risks

Author(s): Melissa A. Pasquinelli<sup>1</sup>, Stephen Little<sup>1</sup>, Michael-Rock Goldsmith<sup>2,\*</sup>, and James Rabinowitz<sup>1</sup>

Affiliation(s): <sup>1</sup>National Center for Computational Toxicology, U.S. EPA, Research Triangle Park, NC; <sup>2</sup>Department of Environmental Science and Engineering, University of North Carolina at Chapel Hill

Application of virtual screening tools based on molecular modeling as a means

Database of Environmental Chemicals

Library of Hormone Receptors

docking via

modeling


In Vivo Omics Indicat

of categorizing and prioritizing chemicals for experimental testing

### Why Molecular Modeling for Evaluating Chemical Toxicity?

Computational methods such as molecular modeling can be used as tools in order to evaluate the potential health and environmental effects of chemicals, particularly when all of the relevant information is not available prior to the risk assessment.

Predictions of a potential toxicological effect of an environmental chemical based on knowledge of the effects of "similar" chemicals





• The availability of atomic-level details of the interactions between environmental chemicals and molecules in the body, such as proteins or DNA



• Integration into *ToxCast*, a multi-level information domain scheme for studying chemical toxicity.

- First phase: Perform a comprehensive study on a set of diverse chemicals across all information domains.
- Second phase: The information that is gathered will be used to extract relationships among the information domains.
- Third phase: Utilize these relationships to inform computer models in order to improve their abilities to suggest priorities for future bioassays and other

regulatory purposes.

This work is a collaboration with Bob Kavlock, David Dix, and Keith Houck from

Molecular modeling tools have been developed primarily for the design of pharmaceuticals. A significant difference between prioritizing toxicity testing and enriching a pharmaceutical database is the relative importance of

which are toxic chemicals that are erroneously categorized as nontoxic. In environmental screens, a false negative may dangerously eliminate a chemical from further testing while in pharmaceutical discovery, the existence of false negatives is much less significant if true positives remain.

## Molecular Modeling Methods for Predicting Chemical Toxicity

## **Methods that Estimate Binding of** Toxicants to Targets

Molecular Descriptors, QSARs Docking into Rigid Macromolecular Targets Docking into Flexible

Mixture of Quantum Mechanics and Molecular Mechanics (OM/MM)

Free Energy Perturbation

## Rigid Docking: Geometry of the macromolecular target

Similar to rigid docking, except that a portion of is rigid while a "best fit" is calculated for a macromolecular target is variety of orientations flexible so that the and geometrical conformations of the binding



## region can to properly fit chemical agents

geometry

### Docking Scoring Functions are Empirically-Based



Docking Scoring

Function





3OH (-)-BaPD axial diol (-)-syn-BcPhDE

Chemical and Physical Properties of Interaction

#### Results

Endocrine Disrupting Compounds (EDCs). The function of nuclear receptors such as the estrogen receptor (ER) is to regulate diverse functions, including reproduction, development, and metabolism. A common mechanism for EDCs is to mimic or inhibit the binding of hormone molecules to these nuclear receptors, which disrupts their normal biological function and can lead to adverse health effects, including cancer. Many natural and synthetic environmental chemicals are suspected to be EDCs.

Flexible docking studies with ERa (right) was used to screen a set of chemicals that represent a wide range of biological activity. This work is a collaboration with Susan Laws from NHEERL


The lack of separation in the docking calculations (right) between chemical agents that do not bind or bind weakly to ERa is an artifact of using tools that are designed for pharmaceuticals.

Docking scoring functions need to be optimized for chemical toxicity focusing on minimizing the false

		Docking Energy
1	[R] EM652	-56.0
	[S] EM652	-60.2
	diethylstilbestrol	-40.5
	mesa-hexestrol	-41.5
	RS-hexestrol	-44.5
	SS-hexestrol	-42.3
	4-hydroxytamoxifen	-60.9
	17b-estradiol (natural ligand)	-43.8
	coumestrol	-44.5
	(R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol	-41.2
	phenol, 4-heptyl	-30.9
	morin	-49.5
	diadzein	-44.3
	ethyl-4-hydroxybenzoate	-31.7
	phenol, 4-chloro-3-methyl	-24.0
	[S] 2-phenyl, 1-propanol	-24.5
	[R] 2-phenyl, 1-propanol	
	1,4-dihydroxy-2-naphthoic acid	-32.9
	5-chloro-2-(2,4-dichlorophenoxyl)phenol	-39.0

**Perfluorinated compounds,** such as PFOA and PFOS, are persistent environmental pollutants that are implicated with binding to the nuclear receptor PPARa, which could result in potential endocrine disrupting properties. PPARs are a family of nuclear receptors that function as transcription factors and regulate multiple metabolic processes. PPAR $\alpha$  is found primarily in the liver and muscle and is linked to fatty acid oxidation and diabetes type II.

PPARα (figure to the right) suggest about 10-100 times increased affinity of the fluorocarbon class relative to the agonist class for the simulated "native" PPARa structure, and a similar order of magnitude as the agonist, CIP, for the activebound conformation.



The picture above depicts the binding pocket of PPARα with and overlay

of the lowest energy pose


for each of the circled

hits (figure to the left).

Polycyclic Aromatic Hydrocarbons (PAHs) are combustion byproducts that are ubiquitous environmental chemicals. Some PAHs are potent animal carcinogens and some PAHs have also been shown to have endocrine

Rigid docking studies with several alpha estrogen receptors (ERα) of the native ligands (top) and PAH metabolites

` ,	ER-1L2I	ER-1GWR	ER-3ERD	ER-3
	[ETC]	[E2]	[DES]	[0
Diethyl, tetrahydro-chrysene diol (ETC), x-ray	-11.2	-9.2	-8.2	
Estradiol (E2), x-ray	-8.7	-11.0	-8.2	
Diethyl stilbestrol (DES), x-ray	-8.8	-8.0	-9.6	
Tamoxifen (OHT), x-ray	***	***	***	-1
3,9-dihydroxy benzanthracene (2OH BA)	-10.1	-9.1	-9.6	
3,9-dihydroxy 12-methyl BA	-10.0	-8.6	-8.5	
2OH (-)-anti-BaPDE	-10.0	-7.6	-7.2	
3OH (-)-BaPD equatorial diol	-9.8	-8.7	-8.8	
3,9-dihydroxy 12-methyl BA enantiomer	-9.8	-9.5	-8.9	
2OH (+)-anti-BaPDE	-9.6	-7.6	-6.3	
3OH (+)-BaP equatorial diol	-9.4	-8.1	-8.5	
(-)-anti-BaPDE	-9.3	-7.9	-6.4	-
3,9-dihydroxy 7-methyl BA	-9.1	-7.4	-9.0	
(+)-syn-BcPhDE	-8.9	-7.9	-5.9	-
(1) anti PaPDE	_0 0	7.5	6.0	



6.9 4.7 9.1 The PAHs bind best to ER-the ER structure that was crystallized with an ER agonist, tetrahydrochrysene diol (ETC). ETC has a chemical structure similar 7.6 to PAHs (above).

4.8 The ER antagonist, tamoxifen 5.2 (OHT), does not bind to the other three ER crystal structures (indicated by -5.9 due to its large size and the use of rigid docking methods



<sup>\*</sup> This work was supported by EPA Grant CT829471, NHEERL-DESE Cooperative Training in Environmental Research